 | |
| Clinical data | |
|---|---|
| Trade names | Onzeald |
| Other names | NKTR-102 |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | none |
| Metabolites | irinotecan and its metabolites |
| Eliminationhalf-life | 38 days |
| Excretion | mostly via kidneys |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C153H176N20O36[C8H16O4]n (n≈113) |
| Molar mass | 20,900–24,900 g/mol[1] |
Etirinotecan pegol (trade nameOnzeald) is adrug developed byNektar Therapeutics for the treatment of certain kinds ofbreast cancer withbrain metastases. TheEuropean Medicines Agency refused to grant it a marketing authorisation in 2017.[2]
It works as atopoisomerase I inhibitor.[3] Chemically, it consists of four units ofirinotecan (a topoisomerase I inhibitor in use since the late 1990s[4]) linked by carboxymethylglycine andpolyethylene glycol (PEG) chains to a centralpentaerythritol ether, resulting in a much longerbiological half-life (38 days) than that of irinotecan. It is formulated as a dihydrochloride and with 1.2 units oftrifluoroacetate.[1]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |